Erlotinib as 1st Line Treatment in NSCLC Stage IIIB/IV
Status:
Completed
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and toxicity of erlotinib as first line treatment in patients with
locally advanced/metastatic (stages IIIB/IV) NSCLC, with clinical predictors of response to
tyrosine kinase inhibitors (erlotinib, gefitinib), such as female gender, never-smoking
status and adenocarcinoma histology. Furthermore, erlotinib-sensitivity will be correlated
with the presence of EGFR mutations in exons 18, 19 and 21, in this population